Results 151 to 160 of about 3,904 (178)

Risankizumab (Skyrizi)

Canadian Journal of Health Technologies, 2023
CADTH recommends that Skyrizi be reimbursed by public drug plans for the treatment of moderately to severely active Crohn disease (CD) if certain conditions are met. Skyrizi should only be covered to treat adult patients with moderately to severely active CD who do not respond to, stop responding to, or who cannot tolerate conventional or ...
openaire   +1 more source

Risankizumab for the treatment of psoriasis

Expert Review of Clinical Pharmacology, 2019
Introduction: The interleukin （IL）-23 and IL-17 pathway is closely related to the pathogenesis of psoriasis. This pathway is considered to be an important target for treating psoriasis. Risankizumab can selectively inhibit IL-23p19 subunit and for the treatment of psoriasis. This article aims to review risankizumab and provides reference for clinicians.
Chuanlan, Gu, Junyi, Yang
openaire   +2 more sources

Risankizumab for psoriasis

The Lancet, 2018
Abigail, Cline, Steven R, Feldman
openaire   +2 more sources

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence

Clinical, Cosmetic and Investigational Dermatology, 2022
Angelo Ruggiero, Matteo Megna, Gabriella Fabbrocini   +2 more
exaly  

Risankizumab-rzaa: A New Therapeutic Option for the Treatment of Crohn’s Disease

Annals of Pharmacotherapy, 2023
David Choi, Shubha Bhat
exaly  

Risankizumab (Skyrizi)

Canadian Journal of Health Technologies
Canada’s Drug Agency (CDA-AMC) recommends that Skyrizi be reimbursed by public drug plans for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, loss of response, or were intolerant to conventional therapy, a biologic treatment, or a Janus kinase (JAK) inhibitor if certain ...
openaire   +1 more source

Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study

Rheumatology, 2023
Andrew Ostor, Ann Eldred, Papp Kim
exaly  

Risankizumab (Skyrizi) for Ulcerative Colitis

The Medical Letter on Drugs and Therapeutics
The injectable interleukin (IL)-23 antagonist risankizumab-rzza (Skyrizi – Abbvie), previously approved by the FDA for treatment of Crohn’s disease (CD), has now been approved for treatment of moderately to severely active ulcerative colitis (UC) in adults. Risankizumab is the first IL-23 antagonist to be approved for treatment of both CD and UC. It is
openaire   +2 more sources

Clinical Evaluation of Risankizumab in the Treatment of Adults with Moderately to Severely Active Crohn’s Disease: Patient Selection and Reported Outcomes

Drug Design, Development and Therapy, 2023
Raymond Cross
exaly  

<p>Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis</p>

Journal of Inflammation Research, 2020
Vidhatha Reddy, Wilson Liao, Bridget Myers   +2 more
exaly